MARKET

JBIO

JBIO

Jade Biosciences Inc
NASDAQ
16.45
-0.08
-0.48%
After Hours: 16.00 -0.45 -2.74% 18:00 12/26 EST
OPEN
16.51
PREV CLOSE
16.53
HIGH
16.83
LOW
16.02
VOLUME
226.06K
TURNOVER
--
52 WEEK HIGH
17.71
52 WEEK LOW
1.016
MARKET CAP
811.22M
P/E (TTM)
-1.4368
1D
5D
1M
3M
1Y
5Y
1D
Jade Biosciences Files For Offering Of 3.2M Shares Of Common Stock By Selling Stockholder
Benzinga · 6d ago
JADE BIOSCIENCES FILES FOR OFFERING OF 3.2 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDER- SEC FILING
Reuters · 6d ago
Weekly Report: what happened at JBIO last week (1215-1219)?
Weekly Report · 6d ago
JBIO Surges Over 75% In Just Two Months On Pipeline Momentum - Did You Take The Bet?
NASDAQ · 12/17 10:15
Jade Biosciences Announces Private Placement Agreement
TipRanks · 12/15 12:28
Jade Biosciences prices 3.21M shares at $14.00 in private placement
TipRanks · 12/15 12:16
Jade Biosciences Raises $45M in Private Stock Offering Of 3.21M Shares At $14/Share To Advance Autoimmune Drug Research
Benzinga · 12/15 12:08
JADE BIOSCIENCES ANNOUNCES $45 MILLION PRIVATE PLACEMENT
Reuters · 12/15 12:00
More
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.

Webull offers Jade Biosciences Inc stock information, including NASDAQ: JBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JBIO stock methods without spending real money on the virtual paper trading platform.